The (near)equivalence of cost-effectiveness and cost-benefit analyses - Fact or fallacy?

被引:22
|
作者
Donaldson, C [1 ]
机构
[1] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland
关键词
Adis International Limited; Economic Evaluation; Streptokinase; Alteplase; Advanced Ovarian Cancer;
D O I
10.2165/00019053-199813040-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
Then has been much recent debate in the health economics literature as to the (near) equivalence of cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). The aim of this paper is to demonstrate that whether such a (near) equivalence exists depends on whether one defines economic evaluations as 'CBA' or 'CEA' on the basis of either what is measured or what question the analyst is seeking to answer. The former basis of definition is popular within the 'decision science' approach to economic evaluation, but does not seem to have any theoretical support. If the latter, more theoretically correct, basis is accepted, there is no longer a case for the (near) equivalence of CBA and CEA.
引用
收藏
页码:389 / 396
页数:8
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PHARMACEUTICALS .5. COST-BENEFIT AND COST-EFFECTIVENESS ANALYSIS OF DRUG-THERAPY
    DAO, TD
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1985, 42 (04): : 791 - 802
  • [32] Cost-Effectiveness and Cost-Benefit Analyses of Providing Menstrual Cups and Sanitary Pads to Schoolgirls in Rural Kenya
    Babagoli, Masih A.
    Benshaul-Tolonen, Anja
    Zulaika, Garazi
    Nyothach, Elizabeth
    Oduor, Clifford
    Obor, David
    Mason, Linda
    Kerubo, Emily
    Ngere, Isaac
    Laserson, Kayla F.
    Edwards, Rhiannon Tudor
    Phillips-Howard, Penelope A.
    WOMENS HEALTH REPORTS, 2022, 3 (01): : 773 - 784
  • [33] Issues of cost-benefit and cost-effectiveness for simulation in health professions education
    Stephen Maloney
    Terry Haines
    Advances in Simulation, 1 (1)
  • [34] Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain
    Simpson, Kit N.
    Fossler, Michael J.
    Wase, Linda
    Demitrack, Mark A.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (15) : 1107 - 1119
  • [35] COST-BENEFIT AND COST-EFFECTIVENESS - METHODOLOGIES FOR EVALUATING INNOVATIVE PHARMACEUTICAL SERVICES
    MCGHAN, WF
    ROWLAND, CR
    BOOTMAN, JL
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1978, 35 (02): : 133 - 140
  • [36] HEALTH-CARE COST-BENEFIT AND COST-EFFECTIVENESS ANALYSIS - AN OVERVIEW
    YIN, DP
    FORMAN, HP
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1995, 6 (03) : 311 - 320
  • [37] Pharmaceutical interventions in the emergency department: cost-effectiveness and cost-benefit analysis
    Miarons, Marta
    Marin, Sergio
    Amenos, Imma
    Campins, Lluis
    Rovira, Montse
    Daza, Manuel
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (03) : 133 - 138
  • [38] Cost-effectiveness and cost-benefit analysis of maintenance measures for open landscapes
    Müller, J
    ECOSYSTEMS AND SUSTAINABLE DEVELOPMENT IV, VOLS 1 AND 2, 2003, 18-19 : 893 - 902
  • [39] Cost-benefit and cost-effectiveness analysis of drug abuse treatment services
    Cartwright, WS
    EVALUATION REVIEW, 1998, 22 (05) : 609 - 636
  • [40] APPLICATION OF COST-BENEFIT AND COST-EFFECTIVENESS ANALYSIS TO CLINICAL-PRACTICE
    BOOTMAN, JL
    MCGHAN, WF
    SCHONDELMEYER, SW
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (03): : 235 - 243